Hemophilia A: The Most Common Bleeding Disorder | Community Health

Hemophilia A, also known as classic hemophilia, is a genetic disorder caused by a deficiency of factor VIII, a protein necessary for blood clotting. It affects approximately 1 in 5,000 to 1 in 10,000 males worldwide, with a significant impact on quality of life. The disorder is inherited in an X-linked recessive pattern, meaning it primarily affects males, while females are often carriers. Symptoms include prolonged bleeding after injury or surgery, joint pain and swelling, and limited mobility. Treatment options include replacement therapy with factor VIII concentrates, desmopressin, and gene therapy. With a vibe score of 6, hemophilia A has a moderate level of cultural energy, reflecting ongoing research and awareness efforts. The controversy spectrum is relatively low, with most debates centered on treatment protocols and access to care. Key figures in the field include Dr. Judith Graham Pool, who developed the first factor VIII concentrate, and organizations like the World Federation of Hemophilia, which advocates for patient rights and access to treatment.